Singular Genomics Systems Inc. (OMIC) NASDAQ
$0.39 0 (0.93%)
Market Cap: $28.75M
As of 04/19/24 11:20 AM EDT. Market closed.
Singular Genomics Systems Inc. (OMIC)
NASDAQ
$0.39
0 (0.93%)
Market Cap: $28.75M
As of 04/19/24 11:20 AM EDT. Market closed.
singular genomics is a venture capital backed biotech company in la jolla, california. we foster a dynamic, fast paced, result oriented environment where we offer employees the opportunity to make a significant impact in a rapidly expanding company. singular genomics is inventing at the forefront of genomics, one of the world’s fastest growing industries. we are located in the center of the ... read more
singular genomics is a venture capital backed biotech company in la jolla, california. we foster a dynamic, fast paced, result oriented environment where we offer employees the opportunity to make a significant impact in a rapidly expanding company. singular genomics is inventing at the forefront of genomics, one of the world’s fastest growing industries. we are located in the center of the biotech hub on the torrey mesa close to the pacific ocean and next door to prestigious institutions like the salk institute, scripps, sanford burnham, and ucsd. we offer free gym membership, 401k plan, competitive health benefits, flexible vacation, and equity incentives, so you can grow as the company grows. we are working to accelerate genomics for the advancement of science and medicine and are passionate about the potential of genomics for improving human health. read less
Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
Spaventa Andrew | Chief Executive Officer | Nov 17, 2023 | Buy | $0.42 | 75,000 | 31,755 | 4,061,206 | Nov 20, 2023, 04:31 PM |
Spaventa Andrew | Chief Executive Officer | Nov 16, 2023 | Buy | $0.41 | 43,468 | 17,857 | 3,986,206 | Nov 20, 2023, 04:31 PM |
Glezer Eli N. | Chief Scientific Officer | Nov 16, 2023 | Buy | $0.43 | 200,000 | 85,640 | 4,570,000 | Nov 20, 2023, 04:30 PM |
Kamdar Kim P. | Director | Aug 14, 2023 | Sale | $0.57 | 77,991 | 44,424 | 3,963,985 | Aug 15, 2023, 07:17 PM |
Kamdar Kim P. | Director | Aug 11, 2023 | Sale | $0.60 | 353,657 | 210,603 | 4,041,976 | Aug 15, 2023, 07:17 PM |
Kamdar Kim P. | Director | Aug 15, 2023 | Sale | $0.53 | 200,000 | 106,960 | 3,763,985 | Aug 15, 2023, 07:17 PM |
Glezer Eli N. | Chief Scientific Officer | May 17, 2023 | Buy | $0.82 | 170,000 | 138,924 | 4,355,000 | May 18, 2023, 08:32 PM |
Glezer Eli N. | Chief Scientific Officer | Dec 12, 2022 | Buy | $2.00 | 50,000 | 100,000 | 4,185,000 | Dec 13, 2022, 06:14 PM |
BARKER DAVID L | Director | Jul 07, 2022 | Option Exercise | $0.63 | 60,000 | 37,800 | 60,000 | Jul 11, 2022, 07:00 PM |
Pellini Michael J | Director | May 31, 2022 | Option Exercise | $0.38 | 154,939 | 58,642 | 254,228 | Jun 07, 2022, 07:30 AM |
Pellini Michael J | Director | May 18, 2022 | Buy | $3.30 | 26,834 | 88,552 | 99,289 | May 19, 2022, 05:01 PM |
Owner | Relationship | Date | Value($) |
Spaventa Andrew | Chief Executive Officer | 11/17/2023 | 31,755 |
Spaventa Andrew | Chief Executive Officer | 11/16/2023 | 17,857 |
Glezer Eli N. | Chief Scientific Officer | 11/16/2023 | 85,640 |
Kamdar Kim P. | Director | 08/14/2023 | 44,424 |
Kamdar Kim P. | Director | 08/11/2023 | 210,603 |
Kamdar Kim P. | Director | 08/15/2023 | 106,960 |
Glezer Eli N. | Chief Scientific Officer | 05/17/2023 | 138,924 |
Glezer Eli N. | Chief Scientific Officer | 12/12/2022 | 100,000 |
BARKER DAVID L | Director | 07/07/2022 | 37,800 |
Pellini Michael J | Director | 05/31/2022 | 58,642 |
Pellini Michael J | Director | 05/18/2022 | 88,552 |
Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
---|---|---|---|---|
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 4,984,871 | 0.04% | No change | Other |
BLACKROCK INC. | 833,595 | 0.00001% | -3.75% | Other |
ORBIMED ADVISORS LLC | 540,697 | 0.00497% | No change | Other |
GEODE CAPITAL MANAGEMENT, LLC | 460,639 | 0.00002% | No change | Other |
RENAISSANCE TECHNOLOGIES LLC | 151,450 | 0.00011% | -1.41% | Other |
Period of Report: 12/31/2023
10-K/10-Q Filings: View